drugset / Trial / NCT02357342
Sirolimus Versus Anti-Vascular Endothelial Growth Factor (antiVEGF) for Wet AMD
RandomizedParallel-groupSingle-blindTreatment
Summary
Phase 2 clinical trial, single site, randomized, subject-masked study to determine safety and efficacy of intravitreal injections of Sirolimus in subjects with wet Age-Related Macular Degeneration (wet AMD) with persistent intraretinal or subretinal edema due to neovascular AMD despite previous AntiVEGF treatment.
Timeline
- Start
- 2015-04
- Primary completion
- 2017-01
- Completion
- 2017-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | — | Intravitreal |
| Comparator | Bevacizumab | Monoclonal antibody | — | Intravitreal |
| Subject | Sirolimus | Small molecule | — | Intravitreal |